Immatics Biotechnologies GmbH:企業の戦略的SWOT分析

◆英語タイトル:Immatics Biotechnologies GmbH - Strategic SWOT Analysis Review
◆商品コード:SWOT20MY2859
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥39,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Immatics Biotechnologies GmbH – Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

Immatics Biotechnologies GmbH (Immatics) is a clinical stage biopharmaceutical company that develops drugs for the treatment of cancer. It develops peptide based active immunotherapy drug candidates based on it novel technology, XPRESIDENT discovery platform. The company has active programs in several tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer. Its major drug candidates include IMA101, IMA201, IMA202, IMA203, and IMA301 which are focused on the development of three ACT approaches ACTolog, ACTengine, and ACTallo to treat cancer. The company has collaborations with Roche, UTHealth and MorphoSys for the advancement of drug candidates. Immatics is headquartered in Tuebingen, Germany.

Immatics Biotechnologies GmbH Key Recent Developments

Feb 21,2020: GSK and Immatics partner on cell therapies for cancer
Nov 12,2019: Immatics Implements Genedata Biologics into proprietary T-cell receptor discovery and engineering XCEPTOR platform
Jul 08,2019: Immatics appoints Harpreet Singh as chief executive officer
May 13,2019: Immatics to present at CIMT Annual Meeting 2019 (May 21-23) in Mainz, Germany
Feb 27,2019: Immatics and Roche to trial combination therapy for solid tumours

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Immatics Biotechnologies GmbH – Key Facts
Immatics Biotechnologies GmbH – Key Employees
Immatics Biotechnologies GmbH – Key Employee Biographies
Immatics Biotechnologies GmbH – Major Products and Services
Immatics Biotechnologies GmbH – History
Immatics Biotechnologies GmbH – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Immatics Biotechnologies GmbH – Business Description
Immatics Biotechnologies GmbH – SWOT Analysis
SWOT Analysis – Overview
Immatics Biotechnologies GmbH – Strengths
Immatics Biotechnologies GmbH – Weaknesses
Immatics Biotechnologies GmbH – Opportunities
Immatics Biotechnologies GmbH – Threats
Immatics Biotechnologies GmbH – Key Competitors
Section 3 – Company’s Lifesciences Financial Deals and Alliances
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Immatics Biotechnologies GmbH, Recent Deals Summary
Section 4 – Company’s Recent Developments
Feb 21, 2020: GSK and Immatics partner on cell therapies for cancer
Nov 12, 2019: Immatics Implements Genedata Biologics into proprietary T-cell receptor discovery and engineering XCEPTOR platform
Jul 08, 2019: Immatics appoints Harpreet Singh as chief executive officer
May 13, 2019: Immatics to present at CIMT Annual Meeting 2019 (May 21-23) in Mainz, Germany
Feb 27, 2019: Immatics and Roche to trial combination therapy for solid tumours
Jan 11, 2019: Immatics at the 18th PepTalk in San Diego, CA
Jan 03, 2019: US Patent Office Grants the 100th Patent to Immatics Underpinning the Company’s Leading Role in the Field of Innovative Immunotherapies
Section 5 – Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

List of Tables
Immatics Biotechnologies GmbH, Key Facts
Immatics Biotechnologies GmbH, Key Employees
Immatics Biotechnologies GmbH, Key Employee Biographies
Immatics Biotechnologies GmbH, Major Products and Services
Immatics Biotechnologies GmbH, History
Immatics Biotechnologies GmbH, Other Locations
Immatics Biotechnologies GmbH, Subsidiaries
Immatics Biotechnologies GmbH, Key Competitors
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Immatics Biotechnologies GmbH, Recent Deals Summary

List of Figures
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Immatics Biotechnologies GmbH:企業の戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bank of America Corp:企業の戦略・SWOT・財務分析
    Bank of America Corp - Strategy, SWOT and Corporate Finance Report Summary Bank of America Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Carmat SAS (ALCAR)-医療機器分野:企業M&A・提携分析
    Summary Carmat SAS (Carmat) is a medical equipment company that offers artificial organs. The company offers development of innovative artificial organs, artificial heart and other vital organs. Its artificial heart products consists of an implantable heart, and components which help connect to an e …
  • Berkley Renewables Inc (BKS)-石油・ガス分野:企業M&A・提携分析
    Summary Berkley Renewables Inc (Berkley) is a venture firm that focuses on capturing opportunities in renewable energy, life sciences, and oil & gas sectors. The company essentially carries out power generation through the management and operation of solar photovoltaic plants . It also undertakes th …
  • Ebix Inc:企業のM&A・事業提携・投資動向
    Ebix Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Ebix Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • TheraVida Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary TheraVida Inc (TheraVida) is a clinical stage specialty pharmaceutical company focused on the development of new therapies for the treatment of primary focal hyperhidrosis. The company’s lead candidate THVD-102 is an oral acting drug used for the treatment of primary and secondary focal hype …
  • Verastem Inc (VSTM):製薬・医療:M&Aディール及び事業提携情報
    Summary Verastem Inc (Verastem) is a clinical-stage biopharmaceutical company with focus on the discovery, development and commercialization of drugs to treat cancer. The company’s lead product candidates include duvelisib, defactinib (VS-6063), FAK inhibitor (VS-4718) and PI3K/mTOR inhibitor (VS-55 …
  • HomeWorks Tri-County Electric Cooperative Inc:企業の戦略的SWOT分析
    HomeWorks Tri-County Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …
  • Seven Bank, Ltd.:企業の戦略・SWOT・財務情報
    Seven Bank, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Seven Bank, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Clinigen Group Plc (CLIN):製薬・医療:M&Aディール及び事業提携情報
    Summary Clinigen Group Plc (Clinigen Group) is a pharmaceutical and services company that provides access to clinical trials, medicines, unlicensed and commercial supply. The company acquires and licenses essential commercial medicines such as foscavir, cardioxane, ethyol, savene and vibativ. It off …
  • Abzena Plc (ABZA)-製薬・医療分野:企業M&A・提携分析
    Summary Abzena Plc (Abzena), formerly Polytherics Group Ltd is a life science company that provides complementary services and technologies to enable the selection, development and manufacture of biopharmaceuticals products based on antibodies and other proteins. The company's technologies include a …
  • Alimentation Couche-Tard Inc. (ATD.B):企業の財務・戦略的SWOT分析
    Alimentation Couche-Tard Inc. (ATD.B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • SOCO International Plc (SIA):石油・ガス:M&Aディール及び事業提携情報
    Summary SOCO International Plc (SOCO) is an oil and gas company that explores, discovers and produces oil and gas reserves. The company offers appraisal and field development services. It provides training and skills and support local communities. SOCO produces and supplies natural resources. SOCO h …
  • Engro Corp Ltd (ENGRO):企業の財務・戦略的SWOT分析
    Engro Corp Ltd (ENGRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • BioClin Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary BioClin Therapeutics Inc (BioClin) is a clinical stage biotechnology company developing protein therapeutics for genetic disorders. Its lead product candidate B-701 is a human monoclonal antibody which targets the activity of FGFR3 (fibroblast growth factor receptor 3) and does not interact …
  • Abg Sundal Collier Holding Asa
    Abg Sundal Collier Holding Asa - Strategy, SWOT and Corporate Finance Report Summary Abg Sundal Collier Holding Asa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • General Cable Corp:電力:M&Aディール及び事業提携情報
    Summary General Cable Corp (General Cable), a subsidiary of Prysmian Group, produces and sells wires and cables. It develops, designs, manufactures, markets and distributes copper, aluminum and fiber optic wire and cable products for the energy, industrial, specialty, construction and communications …
  • Support.com, Inc. (SPRT):企業の財務・戦略的SWOT分析
    Support.com, Inc. (SPRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Formycon AG (FYB):企業の財務・戦略的SWOT分析
    Summary Formycon AG (Formycon) formerly Nanohale AG is a biopharmaceutical company that develops biosimilar drugs candidates. The company offers biopharmaceutical imitation products for global recovery. It provides four biosimilar products in pre-clinical and clinical testing phases. Formycon’s pipe …
  • Autotelic Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Autotelic Inc (Autotelic) is a therapeutic drug monitoring company that develops novel treatments using its therapeutic drug monitoring (TDM) services. The company's pipeline products include devices to improve safety and efficacy of COX-2 inhibitors, paclitaxel nanomedicine, TGF-beta inhibi …
  • Central Glass Co Ltd (4044):企業の財務・戦略的SWOT分析
    Central Glass Co Ltd (4044) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆